CG Oncology (NASDAQ:CGON) Director James Mulay Sells 1,964 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 1,964 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $60.12, for a total value of $118,075.68. Following the completion of the transaction, the director owned 654 shares in the company, valued at approximately $39,318.48. This represents a 75.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Mulay also recently made the following trade(s):

• On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The stock was sold at an average price of $73.01, for a total value of $1,138,956.00.

CG Oncology Stock Performance

CGON traded up $0.73 during midday trading on Tuesday, reaching $60.28. 530,632 shares of the company were exchanged, compared to its average volume of 1,174,573. CG Oncology, Inc. has a one year low of $23.65 and a one year high of $75.50. The stock has a market capitalization of $5.32 billion, a P/E ratio of -25.87 and a beta of 0.31. The stock’s 50-day simple moving average is $64.89 and its 200 day simple moving average is $56.73.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The business had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. On average, research analysts anticipate that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

Analysts Set New Price Targets

CGON has been the topic of several recent analyst reports. Wall Street Zen cut CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Royal Bank Of Canada lifted their price objective on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a report on Monday, May 11th. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a report on Monday, May 18th. Wedbush lifted their price objective on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Finally, Truist Financial reissued a “buy” rating and issued a $82.00 target price (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. NFSG Corp bought a new position in CG Oncology during the first quarter worth $34,000. Comerica Bank increased its stake in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after purchasing an additional 515 shares during the period. LPL Financial LLC lifted its holdings in shares of CG Oncology by 9.8% during the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock worth $257,000 after buying an additional 551 shares in the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CG Oncology during the fourth quarter worth $27,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of CG Oncology by 33.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock worth $163,000 after buying an additional 972 shares in the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.